ModifiedUnitedHealthcarePolicy CS165NE.E

Genetic Testing for Neurological Disorders (for Nebraska Only)

Defines coverage policy for multi-gene genetic testing for heritable neurological disorders for UnitedHealthcare members in Nebraska, including when targeted panels (>=5 genes) are considered medically necessary and when comprehensive panels are not.

Policy Summary

PayerUnitedHealthcare

PolicyGenetic Testing for Neurological Disorders (for Nebraska Only)

Policy CodePolicy CS165NE.E

Change TypeMaterial coverage revisions and code removals

Effective DateJan 1, 2026

Next Review DateN/A

Key ActionOrder multi-gene targeted panels (≥5 genes) only when a specialist documents signs/symptoms and expected impact on management.

SourceLink

POLICY UPDATE CHANGES

Multi-gene Targeted Panel testing (five or more genes) for neurological disorders is proven and medically necessary when all specified criteria are met.

Comprehensive Panel tests intended to evaluate multiple genes associated with multiple categories of clinically distinct neurological disorders are unproven and not medically necessary.

Removed CPT codes 0417U, 81440, 81460, and 81465.

Medical records documentation language was added clarifying that documentation may be required to assess clinical criteria and must support medical necessity.

5+Threshold for panels

NebraskaState applicability

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Comprehensive panels NMN

81448,0216UExample codes listed

Coverage Criteria

Medically Necessary: Multi-gene Targeted Panel Testing

ALL of the following

The individual to be tested displays signs or symptoms of a heritable neurological disorder and the results are expected to directly impact medical management of that disorder.
The test is ordered by, or in consultation with, a medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist.
The test is intended to establish a genetic cause for any one of the following:
- Congenital or Metabolic Myopathy.
- Ataxia.
- Peripheral neuropathy.
- Hereditary spastic paraplegia.
- Muscular dystrophy.

Not Medically Necessary: Comprehensive Panel Testing

ALL of the following

The panel includes genes spanning multiple, clinically distinct neurological disorder categories where the panel is not targeted to a single clinical presentation or specific differential diagnosis.
There is insufficient evidence that testing the wide range of genes on the panel improves diagnostic yield or patient management compared with targeted testing strategies.

Tests billed using removed CPT codes (see history) are not supported by this policy and may be denied. Providers should verify current applicable codes before submitting prior authorization (PA) requests.

Documentation: The patient's medical record must contain documentation that fully supports medical necessity including relevant medical history, physical examination, and results of pertinent diagnostic tests or procedures. Documentation should be legible, maintained in the patient's medical record, and must be made available upon request. Documentation must match the revised Description of Services, updated clinical evidence, and supporting information in this policy.

Prior Authorization

Provider Actions — Billing / Prior Authorization

Prior Authorization Required. Prior authorization is required for multi-gene targeted panel testing and for review of claims involving panel-based genetic testing. Providers must verify the applicable CPT code list and update prior authorization submissions to use current, supported CPT codes. Submissions that include removed CPT codes (0417U, 81440, 81460, 81465) should be revised to a supported code prior to submission or may be denied.

Applicable Codes / Prior Authorization: check the UnitedHealthcare provider portal for the current list of applicable CPT codes and PA requirements before submitting.
Check prior authorization after code removals: confirm that PA records have been updated to reflect removal of CPT codes and re-submit if required.
Removed CPT codes — adjust PA submissions: amend any outstanding PAs that referenced removed CPT codes to use the current CPT codes with appropriate documentation.
Verify prior authorization code list: prior to testing, verify the member’s benefits and the payer’s current code list to prevent claim denials.

Denial Risk

Denial triggers for inadequate criteria or documentation

Denial Risk for Comprehensive Panels. Submissions for comprehensive panels that do not meet the targeted panel criteria or that use removed CPT codes are at high risk of denial. Ensure the clinical documentation directly supports the medical necessity criteria described in this policy and that CPT codes used on the claim are currently supported.

Denial triggers include: use of removed CPT codes; lack of documentation of signs/symptoms; absence of ordering/consulting specialist credentialing; panels that span multiple clinically distinct neurological disorder categories without justification.
Removed codes may trigger denial: claims or PA requests using 0417U, 81440, 81460, or 81465 are not supported and may be denied.
No explicit authorization or denial trigger: this section notes actions that may cause denial but does not constitute an individual claim adjudication — each claim is reviewed against member-specific benefits and documented medical necessity.

Covered Indications

inv-105: Establish genetic cause for listed disorders — criteria for coverage when testing must impact management and meet ordering specialist requirement

Covered indications for establishing genetic cause: Testing is intended to establish a genetic cause for one of: Congenital or Metabolic Myopathy; Ataxia; Peripheral neuropathy; Hereditary spastic paraplegia; Muscular dystrophy. Testing must be expected to directly impact medical management and the test must be ordered by, or in consultation with, an appropriate specialist (medical geneticist, developmental pediatrician, or adult or pediatric neuromuscular or neurogenetics specialist).>= 5 genes for multi-gene targeted panels

From Coverage Rationale: targeted panels defined as five or more genes; WES/WGS addressed under separate policy.

inv-106: Establishing genetic cause for listed disorders — must meet ordering and clinical criteria to be covered for multi-gene targeted panels (≥5 genes)

Must meet ALL of the following to be covered for multi-gene targeted panels (≥5 genes):

Establishing genetic cause — ordering and clinical criteria:

Applicable Codes

Applicable Procedure CodesCPT

0216U	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
0217U	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants.
81448	Hereditary peripheral neuropathies (e.g., Charcot-Marie-Tooth, spastic paraplegia), genomic sequence analysis panel, must include sequencing of at least 5 peripheral neuropathy-related genes (e.g., BSCL2, GJB1, MFN2, MPZ, REEP1, SPAST, SPG11, SPTLC1).
81479	Unlisted molecular pathology procedure

Applicable Codesmixed

No codes listed

Applicable Codesmixed

Applicable Codes

Referenced in Summary of Changes; specific codes not listed in these chunks.